Lymphoma<\/strong><\/h3>\n\n\n\nBased on clinical trials and laboratory research presented at the AACR Dead Sea International Conference on Advances in Cancer Research in 2010, researchers believe there is promise that fucoidan may come forth as an effective lymphoma treatment within the next several years. The major sulfated polysaccharide has been demonstrated to inhibit the growth of malignant DLBCL lymphatic cell lines, while leaving healthy cells functional and intact. Further, a 2015 clinical study published by the Acta Biochimica et Biophysica Sinica <\/em>(ABBS) journal of biochemistry and cell biology found that fucoidan treatment halted G0\/G1 cell cycles, meaning tumor cells were prevented from dividing, reproducing, and proliferating in diffuse large B-cell lymphoma. This study was conducted in vitro and in vivo, utilizing cell culture techniques, Western Blot analysis, cell cycle analysis, and tumor xenograft modeling.<\/p>\n\n\n\n